AAM
CPRX

Advisors Asset Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Advisors Asset Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.4M Sell
177,703
-1,464
-0.8% -$34.9K 0.07% 364
2025
Q4 		$4.18M Sell
179,167
-13,481
-7% -$300K 0.07% 369
2025
Q3 		$3.8M Buy
192,648
+1,132
+0.6% +$23.3K 0.06% 403
2025
Q2 		$4.16M Buy
191,516
+12,650
+7% +$299K 0.07% 357
2025
Q1 		$4.34M Buy
178,866
+12,819
+8% +$289K 0.08% 321
2024
Q4 		$3.47M Sell
166,047
-11,286
-6% -$242K 0.06% 411
2024
Q3 		$3.53M Buy
177,333
+11,484
+7% +$213K 0.06% 397
2024
Q2 		$2.57M Sell
165,849
-59,226
-26% -$922K 0.05% 471
2024
Q1 		$3.59M Buy
225,075
+24,575
+12% +$370K 0.07% 354
2023
Q4 		$3.37M Sell
200,500
-118,480
-37% -$1.62M 0.07% 357
2023
Q3 		$3.73M Sell
318,980
-3,374
-1% -$45.1K 0.08% 316
2023
Q2 		$4.33M Buy
322,354
+3,606
+1% +$51.9K 0.09% 284
2023
Q1 		$5.28M Buy
318,748
+905
+0.3% +$14.9K 0.11% 229
2022
Q4 		$5.91M Buy
317,843
+66,650
+27% +$1.03M 0.12% 187
2022
Q3 		$3.22M Buy
251,193
+2,671
+1% +$31.7K 0.07% 334
2022
Q2 		$1.74M Buy
248,522
+113,743
+84% +$834K 0.03% 561
2022
Q1 		$1.12M Buy
134,779
+90,820
+207% +$642K 0.02% 771
2021
Q4 		$298K Buy
+43,959
New +$289K ﹤0.01% 1136

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Advisors Asset Management's CPRX Position: Q1 2026 in Review

Advisors Asset Management reduced its Catalyst Pharmaceutical (CPRX) stake by 0.82% in Q1 2026, selling an estimated $34.9K and leaving 177,703 shares worth $4.4M. The position accounts for 0.07% of the portfolio, ranked #364.

Advisors Asset Management first reported a position in CPRX in Q4 2021 and has held it in 18 quarters since. The position peaked at $5.91M in Q4 2022. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Advisors Asset Management held 177,703 shares of Catalyst Pharmaceutical worth $4.4M as of Q1 2026.
  • Advisors Asset Management sold 1,464 Catalyst Pharmaceutical shares in Q1 2026, an estimated $34.9K.
  • Catalyst Pharmaceutical made up 0.07% of Advisors Asset Management's portfolio in Q1 2026, its #364 holding.
  • Advisors Asset Management first reported a position in Catalyst Pharmaceutical in Q4 2021 and has held it in 18 quarters since.
  • Advisors Asset Management's Catalyst Pharmaceutical position peaked at $5.91M in Q4 2022.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Advisors Asset Management's 13F filing for Q1 2026, filed 15 May 2026.